Safety and Survival Outcomes of<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior<sup>223</sup>Ra treatment: The RALU Study
Kambiz Rahbar(German Cancer Research Center), Oliver Sartor(Mayo Clinic), Ralph A. Bundschuh(University of Augsburg), Markus Essler(University Hospital Bonn), Anja Schmall(Bayer (Switzerland)), Christian la Fougère(German Center for Neurodegenerative Diseases), Ergela Hasa, Philipp Rassek(University of Münster), Kim M. Pabst(West German Heart and Vascular Center Essen), Vikas Prasad(Washington University in St. Louis), Wolfgang P. Fendler(Essen University Hospital), Milena Kurtinecz(Bayer (United States)), Frank Verholen(Bayer (Switzerland)), Matthias Eiber(University of California, Los Angeles), Helmut Dittmann(University of Tübingen)
Cited by 37
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease
|Nature Medicine|2019|948
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
|The Lancet Oncology|2014|491
Immunohistochemical Validation of PSMA Expression Measured by <sup>68</sup>Ga-PSMA PET/CT in Primary Prostate Cancer
|Journal of Nuclear Medicine|2017|161